QSP Modeling Shows Pathological Synergism Between Insulin Resistance and Amyloid‐Beta Exposure in Upregulating VCAM1 Expression at the BBB Endothelium
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.13296 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Zengtao Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Vascular Cell Adhesion Molecule-1, Insulin Resistance, Amyloid beta-Peptides, Blood-Brain Barrier. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Type 2 diabetes mellitus (T2DM), characterized by insulin resistance, is closely associated with Alzheimer's disease (AD). Cerebrovascular dysfunction is manifested in both T2DM and AD, and is often considered as a pathological link between the two diseases. Insulin signaling regulates critical functions of the blood–brain barrier (BBB), and endothelial insulin resistance could lead to BBB dysfunction, aggravating AD pathology. However, insulin signaling is intrinsically dynamic and involves interactions among numerous molecular mediators. Hence, a mechanistic systems biology model is needed to understand how insulin regulates BBB physiology and the consequences of its impairment in T2DM and AD. In this study, we investigated the pharmacodynamic effect of insulin on the expression of vascular cell adhesion molecule 1 (VCAM1), a marker of cerebrovascular inflammation. Intriguingly, normal insulin concentrations selectively activated the PI3K‐AKT pathway, leading to decreased VCAM1 expression. However, exposure to supraphysiological insulin levels, which is present in insulin resistance, activated both PI3K‐AKT and MEK–ERK pathways, and increased VCAM1 expression. We developed a mathematical model that adequately described the dynamics of various insulin signaling nodes and VCAM1 expression. Further, the model was integrated with in vitro proteomics and transcriptomics data from AD patients to simulate VCAM1 expression under pathological conditions. This approach allowed us to establish a quantitative systems pharmacology framework to investigate BBB dysfunction in AD and metabolic syndrome, thereby offering opportunities to identify specific disruptions in molecular networks that will enable us to identify novel therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics and Brain Barriers Research Center, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
- Vivian L. Smith Department of Neurosurgery, University of Texas Health Sciences Center, Houston, Texas, USA.
ORCID-Profile: Zengtao Wang, Kevin J Thompson, Sunil Krishnan, Krishna R Kalari, Karunya K Kandimalla
Förderung
- NIA NIH HHS
- NINDS NIH HHS
Zitieren
APA
Wang, Z., Veerareddy, V., Tang, X., Thompson, K. J., Krishnan, S., Kalari, K. R., & Kandimalla, K. K. (2025). QSP Modeling Shows Pathological Synergism Between Insulin Resistance and Amyloid‐Beta Exposure in Upregulating VCAM1 Expression at the BBB Endothelium. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13296
Vancouver
Wang Z, Veerareddy V, Tang X, Thompson KJ, Krishnan S, Kalari KR, et al. QSP Modeling Shows Pathological Synergism Between Insulin Resistance and Amyloid‐Beta Exposure in Upregulating VCAM1 Expression at the BBB Endothelium. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.13296
BibTeX
@article{Wang2025,
author = {Wang, Zengtao and Veerareddy, Vaishnavi and Tang, Xiaojiao and Thompson, Kevin J and Krishnan, Sunil and Kalari, Krishna R and Kandimalla, Karunya K},
title = {QSP Modeling Shows Pathological Synergism Between Insulin Resistance and Amyloid‐Beta Exposure in Upregulating VCAM1 Expression at the BBB Endothelium},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.13296}
}
EUVIMED